Review
In this narrative review, the authors evaluate available data on the use of an innovative aerosol foam formulation of calcipotriol plus betamethasone dipropionate (Cal/BD) to treat patients with psoriasis and scalp involvement.
Original Research
This study aimed to evaluate the effectiveness of tildrakizumab in treating moderate-to-severe psoriasis within a real-world setting over a 52-week period in Portugal.
Review
This multicentre, retrospective study evaluates the efficacy and safety of risankizumab in a population of psoriatic patients with palmoplantar involvement over a 52-week treatment period.
Original Research
This study characterizes the sensorial attributes of the calcipotriol
(CAL) and betamethasone dipropionate (BDP) polyaphron dispersion cream vehicle and compares them with the sensorial attributes of conventional formulations for psoriasis such as an ointment and an oleogel product.
Case Report
This article describes four case studies of proactive management with calcipotriol/betamethasone dipropionate foam for the treatment of plaque psoriasis for up to 12 months from initial presentation.
